FDA Approves Moderna’s mFlusiva, the First mRNA Flu Vaccine

The FDA has approved Moderna’s mFlusiva, the first flu vaccine built on mRNA technology — the same platform that powered COVID-19 shots.

Announced August 5, 2026, the vaccine received standard approval for adults aged 50 to 64 and accelerated approval for adults 65 and older, with a post-licensure Phase 4 trial required to confirm benefit in the oldest group.

What the trial showed

In its pivotal study, mFlusiva reduced test-confirmed influenza by 27% compared with a standard-dose flu vaccine in people aged 50 to 64.

The comparator matters for interpreting that number. This is 27% better than an existing vaccine, not 27% effective — a relative improvement on top of whatever protection the standard shot provides, which in a typical season is partial.

Safety was broadly similar, though the mRNA shot caused somewhat more side effects — mostly mild and lasting a day or two. That pattern is familiar from mRNA COVID vaccines and reflects the platform provoking a stronger inflammatory response, which is related to why it generates stronger immunity.

Why the egg problem is the real argument

Traditional flu vaccines are grown in eggs, a months-long process forcing manufacturers to guess each year’s dominant strains far in advance.

The sequence is unforgiving. Strain selection happens roughly six months before the season, based on global surveillance of what is circulating then. Manufacturing follows, hundreds of millions of doses grown in fertilised eggs, and the composition cannot change once it starts.

If the virus drifts in those six months — which it does routinely, being an RNA virus with a high mutation rate under immune pressure — the vaccine is mismatched and effectiveness drops sharply. Some seasons have seen effectiveness fall to low levels for this reason alone.

The second egg problem

Growing virus in eggs also changes it. Influenza adapting to replicate efficiently in egg cells acquires mutations, sometimes in exactly the surface protein the immune response should target.

The resulting vaccine can therefore teach the immune system to recognise a slightly wrong version of the virus — a mismatch introduced by the manufacturing process rather than by viral drift.

mRNA production has no such issue. The sequence is written from the target strain and synthesised chemically, so what the vaccine encodes is what was intended.

What faster manufacturing enables

mRNA vaccines can be made faster, allowing strain choices closer to flu season and potentially better matches — and the platform could speed licensing of pandemic-flu vaccines in a future outbreak.

The pandemic application may be the more consequential. In an influenza pandemic, the interval between identifying the strain and having vaccine available determines how many people are infected before protection exists, and egg-based production takes months that a fast-moving outbreak does not allow.

An established, approved mRNA flu platform shortens that considerably, because the manufacturing process is already validated and only the sequence changes.

A bumpy path

The approval capped an uneven review: the FDA initially declined to consider the application in February 2026, then reversed course a week later, and an expert advisory panel voted unanimously in favour in June.

A refusal to file followed by reversal within a week is unusual and generally indicates an administrative or procedural dispute rather than a substantive objection to the data — a reading the unanimous advisory vote supports.

What the accelerated approval means

The split — standard approval for 50 to 64, accelerated for 65 and older — reflects where the evidence was generated. The pivotal trial studied the younger group, so the older indication rests on extrapolation pending confirmation.

That is the group with most to gain. Influenza mortality concentrates heavily in older adults, and vaccines work less well in them because immune responses weaken with age — which is why higher-dose and adjuvanted formulations exist specifically for that population, and why the Phase 4 result matters.

The uptake problem this enters

A better flu vaccine matters only if people receive it, and coverage has been moving in the wrong direction.

Influenza vaccination rates fall well short of public-health targets in most age groups, including among older adults where the benefit is greatest. Reasons vary — the perception that flu is trivial, the accurate observation that the vaccine sometimes works poorly, and the belief that the shot can cause the illness, which it cannot.

The mRNA platform adds a complication of its own. Confidence in mRNA vaccines became politically contested during and after the COVID pandemic, and a portion of the population now declines them specifically. A flu vaccine on that platform inherits that resistance regardless of its performance.

The counterweight is that the honest case for this vaccine is a better strain match, and mismatch is one of the more legitimate reasons people give for skipping the shot. A vaccine that addresses the actual complaint is at least arguing on the right ground — though whether that changes behaviour is a separate question from whether the immunology is better.

“Flu remains a significant public health challenge, and mFLUSIVA provides an important new option for America’s seniors,” Moderna’s CEO said. The company plans to seek approval in the EU, Canada, Australia and elsewhere. Regulatory news, not medical advice.